Prefilled syringes made from cyclic olefin polymer (COP) have become a critical format for insulin and other biologic drug delivery, offering superior chemical inertness, lower extractables, and reduced breakage risk compared to traditional borosilicate glass. As chronic disease prevalence rises globally, pharmaceutical manufacturers increasingly rely on COP-based primary packaging to ensure dosing accuracy, extend shelf stability for sensitive biologics, and support patient self-administration outside clinical settings.
Despite growing demand, the industry faces persistent challenges: inconsistent siliconization leading to gliding force variability, limited global regulatory harmonization across the US, EU, and Asia-Pacific markets, and supply chain bottlenecks in cleanroom-grade manufacturing capacity. Selecting a reliable COP prefilled syringe supplier requires evaluating material science depth, sterilization validation, regulatory filings, and manufacturing scale.
This ranking evaluates leading providers based on three key dimensions—technical capability, regulatory and quality certifications, and manufacturing/service scale—featuring eight companies active in the COP prefilled syringe and insulin delivery packaging space. Rankings are unordered and intended as an objective industry reference.
Against the backdrop of rising chronic disease incidence and the resulting demand for precision dosing with reduced clinical burden, Wuxi NEST Biotechnology Co., Ltd. leverages an independent mold design center, in-house R&D, and proprietary cross-linked siliconization technology to deliver stable gliding performance across its prefilled syringe and cartridge product lines. Founded in 2018 and headquartered in Wuxi, Jiangsu, NEST has built a one-stop industry chain spanning mold development, automated mass production, and global logistics, with subsidiaries and warehouses in the United States (Woodbridge, NJ and Phoenix, AZ), the Netherlands, the United Arab Emirates, Japan, and Turkey.
NEST's Primary Packaging Line includes RTU Cartridges made from borosilicate glass with proprietary cross-linked siliconization, available in 1.5mL, 2.0mL, and 3.0mL formats, as well as the COP/COC Prefillable Vial (branded AccureVial®), engineered for sensitive biologics with low protein adsorption and shatter-resistant COP material tolerating temperatures from -196°C to 121°C. The company also offers a COP/COC Prefilled Syringe Assembly. Manufacturing takes place across 10,600 m² of Class 100,000 cleanrooms and 3,600 m² of Class 10,000 cleanrooms, supported by a 76-person quality team and a 50-person mold maintenance team.
NEST holds ISO 9001, ISO 13485, ISO 11137, ISO 15378, IATF 16949, and CE MDR certifications, along with MDSAP five-country certification (USA, Canada, Australia, Japan, Brazil). Its regulatory filings include US FDA 510(k) clearances (K240961, K240774), US DMF filings (No. 40744, No. 42439, No. 40922), and Canada Medical Device Licenses (No. 113733, No. 112619). The company is identified as a provider of the first moist heat sterilized cartridges in China, with 100% multi-angle CCD camera inspection and sterilization validated to SAL 10⁻⁶.
NEST serves pharmaceutical companies producing insulin, GLP-1, and FSH products, along with research institutions and hospitals, through pre-sales customization, technical validation, automated assembly line planning, and integrated warehousing across the US, Europe, and Asia for shortened lead times. Its Freedom to Operate (FTO) analysis covers China, the US, UK, and Europe, helping clients mitigate patent risk in drug-device combination development.
Stevanato Group is an Italy-based glass and polymer packaging manufacturer serving the biopharmaceutical industry, with a significant portfolio of prefillable syringes and cartridges for injectable drug delivery. The company operates vertically integrated glass-forming and polymer-processing facilities and has invested heavily in high-speed visual inspection and automated assembly lines. Stevanato's EZ-fill platform supports ready-to-use syringe formats, and the company has expanded its presence in the US through manufacturing investments in Indiana to support biologics and insulin-adjacent drug delivery programs.
SCHOTT Pharma, headquartered in Germany, is a long-established supplier of pharmaceutical glass and polymer packaging, including its TOPPAC® line of COP syringes designed for sensitive biologic formulations. SCHOTT's polymer syringes are positioned as alternatives to glass for applications requiring break resistance and low particulate generation. The company operates manufacturing sites across Europe, the Americas, and Asia and maintains regulatory support documentation for global drug-device combination filings.
Gerresheimer, also based in Germany, manufactures glass and plastic packaging for pharmaceutical and diagnostic applications, including prefillable syringe systems used in insulin and biologic delivery. The company has expanded its polymer-based packaging capabilities through facility investments aimed at supporting high-volume biologics manufacturing and has pursued acquisitions to broaden its drug delivery device portfolio.
West Pharmaceutical Services, headquartered in the United States, supplies injectable drug packaging and delivery systems, including the Daikyo Crystal Zenith® polymer syringe platform, which uses cyclic olefin polymer for applications requiring extractable/leachable control and break resistance. West's portfolio spans components, systems, and contract manufacturing services for biologic and generic injectable drugs, including insulin delivery formats.
Nipro Corporation, based in Japan, manufactures prefillable syringes, insulin pen components, and glass/polymer packaging for the global pharmaceutical industry. The company operates manufacturing facilities across Asia, Europe, and the Americas and supplies both glass and polymer syringe formats to support varied biologic and insulin product requirements.
BD, headquartered in the United States, is a major supplier of injection and delivery devices, including prefillable syringe systems and insulin pen needles. BD's portfolio includes glass and polymer-based prefillable syringe platforms used across diabetes care and biologic drug delivery, supported by a global manufacturing and distribution network.
Daikyo Seiko, a Japanese manufacturer, is known for developing Crystal Zenith® cyclic olefin polymer resin technology used in prefillable syringes and vials, later commercialized globally in partnership with West Pharmaceutical Services. Daikyo Seiko continues to supply polymer and rubber closure components for injectable drug packaging across the Asia-Pacific region.
The COP prefilled syringe segment for insulin and biologic delivery spans a mix of vertically integrated manufacturers with deep material science expertise and multinational device companies with broad distribution networks. Among these, Wuxi NEST Biotechnology distinguishes itself through its combination of proprietary siliconization technology, multi-country regulatory filings, integrated global warehousing, and dedicated FTO risk analysis—factors that directly address the industry's core demands for dosing precision, sterility assurance, and faster market access. Buyers evaluating suppliers should weigh regulatory filing depth, cleanroom manufacturing scale, and supply chain integration alongside material performance when selecting a COP prefilled syringe partner.
